Physician
Oncology
Dr. James R. Berenson, MD
|
|
Give Review
Doctor James R. Berenson, MD practices Oncology. He went to University of California San Diego School of Medicine. University of California San Diego School of Medicine is ranked 17 in research and 19 in primary care medicine James Berenson is a published MD. He published 69 publications, including: 'Synthesis and evaluation of 2-alkylthio-4-(N-substituted sulfonamide)pyrimidine hydroxamic acids as anti-myeloma agents.' James R. Berenson accepts Medicare.
Publications
- Synthesis and evaluation of 2-alkylthio-4-(N-substituted sulfonamide)pyrimidine hydroxamic acids as anti-Myeloma agents.
- The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple Myeloma.
- A phase 3 trial of armodafinil for the treatment of Cancer-related fatigue for patients with multiple myeloma.
- Bone-targeted therapies for Cancer patients and bone cell biology: where do we stand?
- Overexpression of Yin Yang 1 in bone marrow-derived human multiple Myeloma and its clinical significance.
- Carfilzomib in multiple Myeloma.
- Weekly dosing of the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple Myeloma: results from a phase 1 study.
- In vivo models of multiple Myeloma (MM).
- Mutation of NRAS but not KRAS significantly reduces Myeloma sensitivity to single-agent bortezomib therapy.
- Multiple Myeloma: treatment updates.
- Cryoglobulinemia: better treatments with brighter outcomes.
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple Myeloma.
- Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple Myeloma.
- CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple Myeloma.
- Updates in the treatment of multiple Myeloma.
- Comparing effects of kyphoplasty, vertebroplasty, and non-surgical management in a systematic review of randomized and non-randomized controlled studies.
- Multiple Myeloma: improved outcomes with new therapeutic approaches.
- Anti-Myeloma Effects of the Novel Anthracycline Derivative INNO-206.
- Is vertebral augmentation the right choice for Cancer patients with painful vertebral compression fractures?
- TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target.
- A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple Myeloma pat...
- Metatarsal stress fractures in patients with multiple Myeloma treated with long-term bisphosphonates: a report of six cases.
- Antitumor effects of bisphosphonates: from the laboratory to the clinic.
- A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance.
- The Medical Research Council Myeloma IX Trial: New Clinical Insights on the AntiCancer Effects of Zoledronic Acid in Patients With Multiple Myeloma.
- Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple Myeloma patients (the ZMAX trial).
- Prognostic factors and jaw and renal complications among multiple Myeloma patients treated with zoledronic acid.
- Overexpression of yin yang 1 in the pathogenesis of human hematopoietic Malignancies.
- Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series.
- Therapeutic options in the management of Myeloma bone disease.
- Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
- Regulation of Prostate-specific antigen expression by the junctional adhesion molecule A.
- Pleiotrophin produced by multiple Myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis.
- A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple Myeloma.
- Advancing treatment for metastatic bone Cancer: consensus recommendations from the Second Cambridge Conference.
- Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
- New drugs in multiple Myeloma.
- NF-kappaB in the pathogenesis and treatment of multiple Myeloma.
- Pleiotrophin, a multifunctional angiogenic factor: mechanisms and pathways in normal and pathological angiogenesis.
- Proteasome inhibitors: closing the garbage can opens up new therapeutic options for patients with B-cell Malignancies.
- Pleiotrophin is highly expressed by Myeloma cells and promotes Myeloma tumor growth.
- Secretion of pleiotrophin stimulates breast Cancer progression through remodeling of the tumor microenvironment.
- A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple Myeloma.
- Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple Myeloma.
- Dominant negative pleiotrophin induces tetraploidy and aneuploidy in U87MG human glioblastoma cells.
- Arsenic compounds in the treatment of multiple Myeloma: a new role for a historical remedy.
- Advances in treating metastatic bone Cancer: summary statement for the First Cambridge Conference.
- Treatment for Myeloma bone disease.
- Managing bone complications of solid Tumors.
- Bone complications in multiple Myeloma.
- Treatment strategies for skeletal complications of Cancer.
- Pathophysiology of bone metastases.
- Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple Myeloma.
- Safety of prolonged therapy with bortezomib in relapsed or refractory multiple Myeloma.
- Circulating endothelial progenitor cells in multiple Myeloma: implications and significance.
- Recommendations for zoledronic acid treatment of patients with bone metastases.
- Supportive care in Myeloma.
- A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractor...
- Treatment strategies for Myeloma bone disease.
- Estimating the impact of new clinical trial proven Cancer therapy and Cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.
- Overcoming drug resistance in multiple Myeloma: the emergence of therapeutic approaches to induce apoptosis.
- A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory mul...
- The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple Myeloma tumor cells to chemotherapeutic agents.
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple Myeloma: an evidence-based review.
- Advances in the biology and treatment of Myeloma bone disease.
- Treatment of hypercalcemia of malignancy with bisphosphonates.
- Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple Myeloma.
- Maintenance therapy with alternate-day prednisone improves survival in multiple Myeloma patients.
Schools
University of California At San Diego
Conditions Treated
- Acute Leukemia
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Utah -
University of California San Diego School of Medicine
Hospital
-
Cedars-Sinai Medical Center
Drug Facts
| NPI NUMBER | 1124051560 | |
| NPPES Provider LastName | BERENSON | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 900693701 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 1159.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 77.0 | |
| Percent Opioid Claims | 6.64 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124051560 |
| Last Name Of The Provider | BERENSON |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
|
Dr. Robert A. Figlin, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Ronald B. Natale, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gauri D. Kelekar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles A. Forscher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gregory P. Sarna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William M. Audeh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael B. Engelberg, MD
This Doctor is OpenDoctor Recommended.
|